Transvaginal Mesh LawsuitsAugust 2, 2011
Recently, an El Paso woman filed a transvaginal mesh lawsuit against American Medical Systems (AMS) due to issues with her vaginal mesh implant manufactured by American Medical Systems (AMS). She received the AMS vaginal sling in June 2009 in order to fix vaginal tissue.
After the surgery for her pelvic organ prolapse (POP), she endured extreme pain, issues with her urinary system and was required to endure more surgeries to take out the AMS transvaginal mesh. She filed her complaint in Los Angeles Superior Court against American Medical Systems (AMS) and some other unnamed manufacturers. Her lawsuit claims that the transvaginal mesh sling eroded, shrunk and part of the sling protruded into her vagina. Her case claims that American Medical Systems (AMS) did not warn patients adequately of the risks of vaginal mesh complications and side effects. She claimed that American Medical Systems (AMS) should be responsible due to strict liability, negligence, and a breach of an implied and express warranty, as well as fraud, misrepresentation, and a violation of California’s consumer protection laws.
Vaginal Mesh Erosion Lawsuits
- ObTape Lawsuit
- Vaginal Mesh Erosion Warning by the FDA
- Bladder Sling Mesh Erosion Lawsuits
- ObTape Mesh Erosion Lawsuits
- Vaginal Mesh, Bladder Slings and ObTape Lawsuits
- Transvaginal Mesh Lawsuits
Several other American Medical Systems (AMS) transvaginal mesh lawsuits have been filed by women experiencing severe complications after receiving surgery implanting transvaginal mesh products to correct their pelvic organ prolapse (POP). In 2008 the FDA issued a warning saying that in ‘rare cases’ severe side effects and complications may result after implanting transvaginal mesh products. In 2011, the FDA revised their statement to say that it is no longer rare for patients to experience such complications. Some complications from transvaginal mesh products include pain during sex, urinary incontinence, and not fixing the pelvic organ prolapse (POP).
Last year, multiple individuals reached settlements through Mentor ObTape transvaginal mesh lawsuits after experiencing severe complications with the products. The Mentor ObTape is made by a subsidiary of Johnson & Johnson. The lawsuits claimed that the rate of complications with the Mentor ObTape vaginal mesh product may be as high as 18%. The Mentor ObTape vaginal mesh has since been removed from the market.
Recently there have been an increasing number of Bard Avaulta transvaginal mesh lawsuits filed by women experiencing transvaginal mesh complications with those products. The lawsuits claim that Bard Avaulta’s transvaginal mesh products were negligently designed and that the manufacturer did not warn patients about the potential complications and transvaginal mesh side effects.
If you or a loved one received a transvaginal mesh product from American Medical Systems (AMS) or another manufacturer and you are experiencing complications with the device, you may be entitled to financial compensation.
Transvaginal Mesh Lawsuits: Speak to an Attorney
Many patients suffering from transvaginal mesh injuries wish that they had been warned of the risks and potential complications before undergoing the operation. Our product liability law team at the Willis Law Firm is committed to getting you answers and financial compensation for your medical expenses, loss of income, physical pain, and emotional suffering. Transvaginal mesh products currently linked with transvaginal mesh injuries include:
- Bard Avaulta Solo
- Avaulta Plus
- Avaulta Biosynthetic Systems
If you or a loved one is suffering from transvaginal mesh injuries please call the Willis Law Firm. We have female consultants standing by, trained to discuss sensitive issues confidentially. We are currently accepting Transvaginal Mesh Injuries lawsuits nationwide. All cases are handled on a Contingency Fee Basis (no attorney’s fees or expenses charged unless we recover for you).© Willis Law Firm for Drug Attorneys. Replication strictly prohibited without written consent.